Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Allo-SCT for Hematologic Malignancies
NCT00818961Phase 2Terminated
- Sponsor
- Northside Hospital
- Start
- May 2005
- Primary completion
- Mar 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 8 more, sponsored by Northside Hospital. Primary endpoint: Survival at Day 100. Started May 2005; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
chronic myeloid leukemia (CML)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00818961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00818961.